Navigation Links
Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients
Date:11/1/2008

ith hypersensitivity to ribavirin or any other component of the product, women who are pregnant, men whose female partners are pregnant, patients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia), and patients with creatinine clearance less than 50 mL/min.

Avoid Pregnancy

REBETOL therapy should not be started until a report of a negative pregnancy test has been obtained immediately prior to planned initiation of therapy. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients during therapy and 6 months post-treatment. Patients should use at least two effective forms of contraception and have monthly pregnancy tests during therapy and for 6 months after completion of therapy. A Ribavirin Pregnancy Registry has been established to monitor maternal-fetal outcomes of pregnancies in female patients and female partners of male patients exposed to ribavirin during treatment, and for 6 months following cessation of treatment. Physicians and patients are encouraged to report such cases by calling 1-800-593-2214.

Incidence of Adverse Events

There are no new adverse events specific to PEGINTRON as compared to INTRON A; however, the incidence of some (e.g., injection site reactions, fever, rigors, nausea) were higher. The most common adverse events associated with PEGINTRON were "flu-like" symptoms, occurring in approximately 50% of patients, which may decrease in severity as treatment continues. Application site disorders were common (47%), but all were mild (44%) or moderate (4%) and no patient discontinued, and included injection site inflammation and reaction (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2% of patients receiving PEGINTRON. Alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON.

Psychiatric adverse events, which include insomnia, were common (57%) with PEGINTRON but similar to INTRO
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
2. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
3. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
4. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
5. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
6. Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
9. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
10. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... MARLTON, N.J. , March 4, 2015 ... brand protection and serialization solutions, announced it will be ... Roosevelt Paper. The live event, "How to Boost Manufacturing ... on Wednesday, March 18th at 2:00 PM EDT.  ... Officer for Acsis, and John Gordon , Chief ...
(Date:3/4/2015)... 4, 2015 UPM Pharmaceuticals, a division of ... Sprout Pharmaceuticals to manufacture Flibanserin 100 mg tablets. Sprout ... the first drug approved to treat hypoactive sexual desire ... dysfunction. The tablets will be manufactured at ... Tennessee . Dr. John M. ...
(Date:3/4/2015)... -- Results of the recent study, Results From a ... Positive Margin Detection , were presented as part of ... Annual Miami Breast Cancer Conference last week. ... MD, FACS, Professor of Surgery at the Sackler School ... of MarginProbe,s efficiency and accuracy when used consecutively to ...
Breaking Medicine Technology:UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets 2UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets 3New Study Shows Breast Re-excision Rates Significantly Reduced in 100 Consecutive Cases 2
... Valley Technologies, Inc. (LVT) is pleased to announce ... the U.S. Food and Drug Administration (FDA).  On ... with no Form 483 observations and no discussion ... relating to cGMP (current Good Manufacturing Practices).  Additionally, ...
... MORRISVILLE, N.C., Jan. 9, 2012  nContact, Inc., the ... its technology will be presented by physicians in ... Atrial Fibrillation Symposium, January 12-14 in Boston, Massachusetts. ... with VisiTrax® and next generation EPi-Sense™ Coagulation System ...
Cached Medicine Technology:nContact's Cardiac Ablation Technology to be Presented in Two Noteworthy Posters at Boston Atrial Fibrillation Symposium 2012 2
(Date:3/4/2015)... (PRWEB) March 04, 2015 With the growing ... the lives of our teens and young adults, combined with ... difficult and confusing to try to keep up with what ... fad or trend is replaced on a daily basis. , ... substances, and the slang that is used to discreetly talk ...
(Date:3/4/2015)... 2015 Alliance Healthcare Foundation (AHF), a ... those in need in San Diego and Imperial Counties, ... its Mission Support Grants program with awards totaling $1 ... for AHF’s Mission Support Grants program. Grant recipients were ... trustees and program committee, as well as the community ...
(Date:3/4/2015)... 04, 2015 The Global Liquefied ... in 2014 and is estimated to grow to ... 4.0% from 2014 to 2019. , Browse through ... for an analysis of industry trends, segments & ... liquefied petroleum gas market is classified into source, ...
(Date:3/4/2015)... RapidScale, a global cloud services innovator, is attending ... 16th-18th. They are hosting Booth #1010 on the expo ... engineering executives in attendance to provide demos and discuss ... include William Hiatt, CTO; Jeff Richards, Cloud Delivery Manager; ... Support Manager. , RapidScale is also hosting two ...
(Date:3/4/2015)... According to a new report published ... the U.S. suffer from gastroesophageal reflux disease (GERD), more ... to control acid production, but these can have side ... the problem and lead to other uncomfortable digestive conditions. ... the lower esophageal sphincter does not function properly. Anti-reflux ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom Offers Guide to Parents for Keeping Youth Sober 2Health News:Alliance Healthcare Foundation Awards $1 million through Mission Support Grants Program 2Health News:Alliance Healthcare Foundation Awards $1 million through Mission Support Grants Program 3Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 2Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 3Health News:Rapidscale to Host First Cloudtalk Events at Channel Partners in Las Vegas 2Health News:Rapidscale to Host First Cloudtalk Events at Channel Partners in Las Vegas 3Health News:New and Proven Acid Reflux Treatments Offer Relief to Millions of Americans 2Health News:New and Proven Acid Reflux Treatments Offer Relief to Millions of Americans 3
... been substantially ramped up in Canadian hospitals since the ... infections post-SARS have multiplied even faster, a new Queen,s ... Dick Zoutman, the national survey is a six-year follow-up ... to the outbreak of SARS (Severe Acute Respiratory Syndrome). ...
... SGP ) will webcast its "R&D Update" ... Monday, Nov. 24, 2008. Fred Hassan,Schering-Plough,s chairman and ... Schering-Plough Research Institute, and other,members of management will ... is to provide an update on the company,s ...
... increase risk 8-fold, researchers say , , FRIDAY, Nov. 7 ... is not healthy for you, but now a new ... among obese smokers. , "We know that obesity and ... lead researcher Annemarie Koster, an epidemiologist at the U.S. ...
... Nov. 7 Triple-S,Management Corporation (NYSE: GTS ... Chief Executive Officer, and Juan-Jose Roman,Finance Vice President ... at the Credit Suisse 2008 Healthcare Conference in ... time. The presentation will be,broadcast live through the ...
... cholesterol tests that identify the risk of heart disease ... Add the responsibility of providing sustained care for ... important. , Yet, grandmothers in the first two years ... to protect their health compared to grandmothers the same ...
... disease of biblical times, leprosy, also known as Hansen,s ... "Approximately 150 cases are diagnosed each year with ... leprosy, says James Krahenbuhl, Ph.D., director of the Health ... Baton Rouge, LA. "We believe there are more cases ...
Cached Medicine News:Health News:'Superbugs' on the rise in Canadian hospitals, new Queen's study shows 2Health News:Smoking Coupled With Obesity Raises Death Risk 2Health News:Smoking Coupled With Obesity Raises Death Risk 3Health News:Triple-S Management Corporation to Present at Credit Suisse 2008 Healthcare Conference 2Health News:The health burden of raising a grandchild 2Health News:The health burden of raising a grandchild 3Health News:Forgotten, but not gone: Leprosy still present in the US 2
... system represents a breakthrough for patients experiencing ... The system gathers bone during decompression, bone ... bone into the implant's chamber produces a ... from the iliac crest. The BAK/C implant ...
Intera 3.0T is the most compact high-field clinical whole-body MR system in the world, bringing 3.0T capabilities "out of the tunnel" and into the light of an open, patient-friendly design....
... Intradiscal Instruments are designed to provide ... aid in disc removal, endplate preparation, ... set consists of several Vertebral Spreaders, ... and a Vertebral Body Positioner. Used ...
... Platelet Concentrate System is a point-of-care system ... Concentrate (also referred to as Platelet Rich ... (PPP) from a small sample of blood. ... natural growth factors, which are found in ...
Medicine Products: